MIR592

Summary

MIR592 (microRNA 592, HGNC:32848) is a microRNA gene on chromosome 7q31.33.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 693177 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32848
Approved symbol	MIR592
Name	microRNA 592
Location	7q31.33
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-592
Ensembl gene	ENSG00000207692
Ensembl biotype	miRNA
Entrez	693177
RNAcentral	URS000075E152 — miRNA, 97 nt, 19 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384959

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384959 — 1 exons

Exon	Start	End
ENSE00001499966	127058088	127058184

Expression profiles

Bgee: expression breadth broad, 23 present calls, max score 76.82.

Top tissues by expression

23 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
intestine	UBERON:0000160	76.82	gold quality
monocyte	CL:0000576	74.12	gold quality
stomach	UBERON:0000945	72.84	gold quality
blood	UBERON:0000178	72.61	gold quality
kidney	UBERON:0002113	72.39	gold quality
corpus callosum	UBERON:0002336	71.24	gold quality
putamen	UBERON:0001874	69.76	gold quality
omental fat pad	UBERON:0010414	69.59	gold quality
lower esophagus muscularis layer	UBERON:0035833	67.08	gold quality
vagina	UBERON:0000996	64.97	gold quality
minor salivary gland	UBERON:0001830	64.96	gold quality
nucleus accumbens	UBERON:0001882	63.99	gold quality
amygdala	UBERON:0001876	63.26	gold quality
right hemisphere of cerebellum	UBERON:0014890	63.24	gold quality
left lobe of thyroid gland	UBERON:0001120	60.83	gold quality
tibial artery	UBERON:0007610	59.78	gold quality
caudate nucleus	UBERON:0001873	59.21	gold quality
liver	UBERON:0002107	59.05	silver quality
upper lobe of left lung	UBERON:0008952	56.93	gold quality
Brodmann (1909) area 9	UBERON:0013540	56.00	gold quality
right lobe of thyroid gland	UBERON:0001119	53.19	gold quality
left testis	UBERON:0004533	41.61	gold quality
right testis	UBERON:0004534	34.92	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.49

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 20)

• miR-552 and miR-592 were overexpressed in primary colorectal cancer relative to primary lung adenocarcinomas (PMID:24778034)
• miR-592 functioned as a novel and potential carcinogen-initiated and metastasis-related biomarker in colorectal cancer. (PMID:25661360)
• The expression of miR-592 and its effects on LHCG receptors in patients with polycystic ovary syndrome and normal controls are described. (PMID:26679164)
• miR-592 targets DEK transcript and suppresses hepatocellular carcinoma cell growth (PMID:26722432)
• our clinical data and functional studies suggest that miR-592 is a new robust inhibitor of the Warburg effect and a promising therapeutic target for hepatocellular carcinoma treatment (PMID:27153552)
• These data suggest that miR-592 may promote the progression and metastasis, in part, by targeting FoxO3A in colorectal cancer (PMID:27167185)
• We developed a miRNA expression signature that may be predictive for the risk of distant relapse in early stage CC and confirmed previously reported association between miR-592 expression and MMR status. (PMID:27485175)
• mechanistic investigations defined insulin-like growth factor binding protein 2 (IGFBP2)as a direct and functional downstream target of microRNA-592, which was involved in the microRNA-592-mediated tumor-suppressive effects in glioma cells. (PMID:28718372)
• these data suggest that miR-592 may exert it suppressive role in breast cancer, at least in part, by targeting TGFbeta-2, and that miR-592 may be a novel target for breast cancer treatment (PMID:29039599)
• Overexpression of miR-592 promotes GC proliferation, migration, and invasion and induces the EMT via the PI3K/AKT and MAPK/ERK signaling pathways by inhibiting Spry2, suggesting a potential therapeutic target for Gastric cancer. (PMID:29949784)
• The results of this study showed that miR-592 targets the ROCK1 transcript and suppresses glioma cell growth and invasive growth, thereby providing (PMID:30169426)
• findings suggest that miR-592 acted as a tumor suppressor by targeting ROCK1 and may serve as a potential biomarker in acute myeloid leukemia (PMID:30840284)
• The results indicated that the NEAT1/miR592/NOVA1 pathway may play regulatory roles in thyroid cancer malignancy in vitro and in vivo. Our findings may provide novel insight into the pathogenesis of thyroid cancer. (PMID:31524231)
• The Potential Role of Selected miRNA in Uveal Melanoma Primary Tumors as Early Biomarkers of Disease Progression. (PMID:32131485)
• miR592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclindependent kinase 8. (PMID:32945439)
• LncRNA WTAPP1 promotes proliferation of laryngeal carcinoma cells through regulating microRNA-592. (PMID:33015795)
• MicroRNA592 promotes cell proliferation, migration and invasion in colorectal cancer by directly targeting SPARC. (PMID:33576452)
• The regulation of microRNA in each of cancer stage from two different ethnicities as potential biomarker for breast cancer. (PMID:34029828)
• MiR-592 activates the mTOR kinase, ERK1/ERK2 kinase signaling and imparts neuronal differentiation signature characteristic of Group 4 medulloblastoma. (PMID:34274968)
• MicroRNA-592 Inhibits the Growth of Ovarian Cancer Cells by Targeting ERBB3. (PMID:36916303)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir592	ENSMUSG00000076067

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.